A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Elevidys was granted expanded approval by the U.S. Food ... Górecki et al, Is dystrophin immunogenicity a barrier to ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

The determination comes after recruitment and dosing in certain trials were paused after a young patient died due to acute ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is crucial for gene therapy delivery in Duchenne muscular dystrophy (DMD).

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular dystrophy, did not achieve its primary endpoint, according to findings ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

CAMBRIDGE, Mass., April 04, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following update related to ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short ... the treatment with gene therapy such as Elevidys (delandistrogene moxeparvovec) aimed at ...